Bharat Biotech released the results from the Phase 3 trials of Covaxin, claiming it demonstrated overall vaccine efficacy of 77.8 per cent against symptomatic coronavirus. The Hyderabad-based multinational biotechnology company shared the final Phase-3 data published on medRxiv, saying Covaxin has been proven ‘safe’ in India’s largest efficacy trial. Bharat Biotech conducted a double-blind, randomised, multicentre, phase 3 clinical trial in 25 Indian hospitals to evaluate the vaccine's efficacy, safety, and immunological lot consistency. Times Now's Karishma reports the efficacy analysis demonstrates Covaxin is 77.8% effective against symptomatic coronavirus, it is 93.4% effective against severe symptomatic COVID-19. The data also demonstrates that 63.6% gives protection against symptomatic patients and gives 65.2 per cent effective against the Delta variant.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting